Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells

Journal of Digestive Diseases

Volumn 11, Issue 1, 2010, Pages 34-42

  Zhu, Feng Shang ^a   Chen, Xi Mei ^a   Huang, Zhi Gang ^a   Wang, Zhi Rong ^a   Zhang, Dong Wei ^a   Zhang, Xia ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Cyclooxygenase inhibitors; Drug synergism; Gastric cancer; Multidrug resistance

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ROFECOXIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN BGC 823; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ETOPOSIDE; FLUOROURACIL; GENE EXPRESSION REGULATION; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOBLOTTING; LACTONES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; SULFONES;

EID: 76349099613     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00411.x     Document Type: Article

References (32)

1. Mao XY, Wang XG, Lv XJ, Xu L, Han CB. COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J Gastroenterol 2007, 13:3466-71.
2. Dong M, Guda K, Nambiar PR. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003, 24:307-15.
3. Miyashita M, Makino H, Katsuta M. Cyclooxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma. J Nippon Med Sch 2006, 73:308-13.
4. Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA, Cummings WO. Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia 2006, 8:437-45.
5. Asano T, Shoda J, Ueda T. Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 2002, 8:1157-67.
6. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG, Mokbel K. Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol 2007, 96:424-8.
7. Sipponen P. Gastric cancer: pathogenesis, risks, and prevention. J Gastroenterol 2002, 37(13):39-44. Suppl
8. Blanke CD, Mattek NC, Deloughery TG, Koop DR. A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat 2005, 75:169-72.
9. Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2:299-305.
10. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003, 4:605-15.
11. Vainio H, Morgan G. Non-steroidal anti-inflammatory drugs and chemoprevention of cancer. Ann Chir Gynaecol 2000, 89:173-6.
12. Sawaoka H, Kawano S, Tsuji S. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998, 274:G1061-7.
13. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005, 4:1358-63.
14. Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 2007, 67:4915-23.
15. Ratnasinghe D, Daschner PJ, Anver MR. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 2001, 21:2141-7.
16. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002, 277:38915-20.
17. Zhu FS, Chen XM, Wang YJ, Zhang X, Feng JX. Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro. Zhonghua Zhong Liu Za Zhi 2007, 29:186-8.
18. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-24.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
20. Chen CJ, Chin JE, Ueda K. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-9.
21. Cowell IG, Dixon KH, Pemble SE, Ketterer B, Taylor JB. The structure of the human glutathione S-transferase pi gene. Biochem J 1988, 255:79-83.
22. Ikuta K, Takemura K, Sasaki K. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 2005, 28:707-12.
23. Jimenez P, Garcia A, Santander S, Piazuelo E. Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option? Curr Pharm Des 2007, 13:2261-73.
24. Tendo M, Yashiro M, Nakazawa K. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 2006, 244:247-51.
25. Arber N, Eagle CJ, Spicak J. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-95.
26. Saukkonen K, Rintahaka J, Sivula A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003, 111:915-25.
27. Cho SJ, Kim N, Kim JS, Jung HC, Song IS. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci 2007, 52:1713-21.
28. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother Pharmacol 2000, 45:389-96.
29. Ruggeri RM, Sciacchitano S, Vitarelli E, Trimarchi F, Barresi G, Trovato M. Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas. Arch Pathol Lab Med 2006, 130:1014-9.
30. Zatelli MC, Luchin A, Tagliati F. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 2007, 14:1029-38.
31. Fantappiè O, Masini E, Sardi I. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002, 35:843-52.
32. Andrews P, Zhao X, Allen J, Li F, Chang M. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 2008, 61:203-14.